In a report released yesterday, Hassan Al-Wakeel from Barclays maintained a Hold rating on Siemens Healthineers AG (SEMHF – Research Report), with a price target of EUR49.00. The company’s shares closed last Tuesday at $56.50.
According to TipRanks.com, Al-Wakeel is ranked #2793 out of 7590 analysts.
Currently, the analyst consensus on Siemens Healthineers AG is a Moderate Buy with an average price target of $62.98.
Based on Siemens Healthineers AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.97 billion and net profit of $443 million. In comparison, last year the company earned revenue of $3.69 billion and had a net profit of $411 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.